Desmoplastic Small Round Cell Tumor (DSRCT) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Changing incidence and survival of desmoplastic small round cell tumor in the USA
Proc (Bayl Univ Med Cent). 2022 Mar 22;35(4):415-419. doi: 10.1080/08998280.2022.2049581. eCollection 2022.ABSTRACTThe incidence and prognosis of desmoplastic small round cell tumor (DSRCT) is inadequately understood. Survival analysis for DSRCT has not been investigated in a population-based study. We conducted a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) 9 Registry (1975-2018). Annual percent changes in incidence were estimated using SEER*Stat, and risk ratios were estimated using Poisson regression. Cox regression models were constructed to estimate the hazard ratio for survi...
Source: Baylor University Medical Center Proceedings - June 27, 2022 Category: Universities & Medical Training Authors: Syed Hamza Bin Waqar Hassam Ali Source Type: research

Targeting the FAK-Src Complex in Desmoplastic Small Round Cell Tumors, Ewing Sarcoma, and Rhabdomyosarcoma
We examined the effects of targeting the FAK-Src complex by addressing (p)FAK and (p)Src expressions in tumor sections of DSRCT (n = 13), ES (n = 68), ARMS (n = 21), and ERMS (n = 39) and by determining the antitumor effects of single and combined treatment with FAK inhibitor defactinib and multikinase (Abl/SFK) inhibitor dasatinib in vitro on cell lines of each subtype. In vivo effects were assessed in DSRCT and ERMS models. Concurrent pFAK and pSrc expressions (H-score >50) were observed in DSRCT (67%), ES (6%), ARMS (35%), and ERMS (19%) samples. Defactinib treatment decreased pFAK expression and reduced cell viabili...
Source: Sarcoma - June 3, 2022 Category: Cancer & Oncology Authors: Anke E M van Erp Melissa H S Hillebrandt-Roeffen Niek F H N van Bree Tim A Pl üm Uta E Flucke Ingrid M E Desar Emmy D G Fleuren Winette T A van der Graaf Yvonne M H Versleijen-Jonkers Source Type: research

Bevacizumab, With Sorafenib and Cyclophosphamide Provides Clinical Benefit for Recurrent or Refractory Osseous Sarcomas in Children and Young Adults
ConclusionsIntravenous bevacizumab combined with oral sorafenib and metronomic cyclophosphamide was tolerated and required minimal supportive care or additional clinic visits. Disease stabilization for prolonged time periods was observed in greater than half of the treated patients. Patients with bone sarcoma demonstrated a signal of activity suggesting possible benefit from incorporation of the therapy as a maintenance regimen in upfront setting, or as a palliative regimen. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - May 25, 2022 Category: Cancer & Oncology Source Type: research

Extracellular Vesicles: A New Source of Biomarkers in Pediatric Solid Tumors? A Systematic Review
Virtually every cell in the body releases extracellular vesicles (EVs), the contents of which can provide a “fingerprint” of their cellular origin. EVs are present in all bodily fluids and can be obtained using minimally invasive techniques. Thus, EVs can provide a promising source of diagnostic, prognostic, and predictive biomarkers, particularly in the context of cancer. Despite advances using EVs as biomarkers in adult cancers, little is known regarding their use in pediatric cancers. In this review, we provide an overview of published clinical and in vitro studies in order to assess the potential of using EV-derive...
Source: Frontiers in Oncology - May 24, 2022 Category: Cancer & Oncology Source Type: research

Trabectedin-irinotecan, a potentially promising combination in relapsed desmoplastic small round cell tumor: report of two cases
We describe two heavily-pretreated young patients with advanced-stage DSRCT given third-line treatment with a combination of trabectedin and irinotecan, based on our preclinical data demonstrating its effect on patient-derived xenografts. This trabectedin-irinotecan treatment showed a limited toxicity. One patient had a mixed response (overall stable disease), the other a complete tumor remission. This is the first report of preliminary findings to suggest that combining trabectedin and irinotecan is worth further investigating as a potentially valuable chemotherapy for DSRCT.PMID:35470779 | DOI:10.1080/1120009X.2022.20677...
Source: Journal of Chemotherapy - April 26, 2022 Category: Cancer & Oncology Authors: Andrea Ferrari Stefano Chiaravalli Luca Bergamaschi Olga Nigro Virginia Livellara Giovanna Sironi Patrizia Gasparini Sandro Pasquali Nadia Zaffaroni Silvia Stacchiotti Carlo Morosi Maura Massimino Michela Casanova Source Type: research